Why scientists are suddenly studying magic mushrooms

For a long time, magic mushrooms lived at the edge of the conversation. Something people whispered about. Something science politely ignored.

That is over. Some of the most serious researchers in the world are now studying psilocybin, the naturally occurring compound in magic mushrooms. Not fringe labs. Places like Baylor College of Medicine, Emory University and Imperial College London. Here is what they are finding, told straight, with the caveats left in.

The study that surprised the longevity world

In 2025, researchers at Baylor and Emory published something unexpected in npj Aging, a Nature partner journal. They treated human cells with psilocin, the active form of psilocybin. The cells lived longer. A lower dose extended cellular lifespan by about 29 percent. A higher dose, about 57 percent. The treated cells showed less oxidative stress, fewer signs of DNA damage, and better preserved telomeres, the protective caps on our chromosomes that wear down as we age.

Then they went further. Aged mice, about 60 in human years, were given psilocybin once a month. The treated mice showed roughly 30 percent better survival than the untreated group. The researchers noted their fur even looked healthier.

One detail caught our eye. The effect came from repeat, spaced doses over time. Not one large experience. A rhythm.

To be clear about what this is: cells in a dish and female mice. It is early science, not a promise. The authors themselves say much more research is needed before anyone calls psilocybin a longevity therapy for humans. But studies like this are why people who never thought about mushrooms are suddenly paying attention.

The depression trial that changed the tone

The mental health research is further along, and psilocybin therapy is moving from breakthrough toward medicine. At Imperial College London, researchers ran a head to head trial comparing psilocybin therapy with escitalopram, a widely prescribed antidepressant. The results were published in the New England Journal of Medicine.

Psilocybin therapy appeared to work more rapidly. And by the end of the six week trial, it was associated with a broader range of improvements than the conventional antidepressant.

The way the lead researcher, Robin Carhart-Harris, described it stays with us. Conventional antidepressants tend to level things out, a kind of emotional blunting. Psilocybin seemed to do something different. People were able to step outside their depression and see things with freshness and objectivity. He called it a relearning process. A recalibration of perspective.

In depression, people fall into fixed, negative ways of seeing themselves and the world. What this research suggests is that psilocybin may help loosen that grip.

What this means, and what it does not

These studies used controlled doses in clinical and laboratory settings, often with therapeutic support. That is a different thing from anything you can buy, including from us. Nothing here is medical advice, and nothing we make is a treatment for any condition. If you are struggling, please talk to a professional you trust. The rules are shifting too: Canada could soon allow psilocybin prescriptions.

And still. For years, our customers have told us their days feel different. Calmer. More present. More open. Kyla told us about a gentle settling in her body after months of fight or flight. Elena told us microdosing changed her life. Harry shared his story here. We never had the studies to point to. Now the world is starting to catch up to what people have been quietly experiencing.

Science is doing its slow, careful work. We will keep following it and sharing what it finds, honestly, caveats and all.

Curious where to begin?

Start gentle. Read our beginner’s guide to microdosing mushrooms, take the two minute quiz to find your dose, or meet EasyDays, our gentlest place to start.

Sources: Kato et al., Psilocybin treatment extends cellular lifespan and improves survival of aged mice, npj Aging (2025). Carhart-Harris et al., Trial of Psilocybin versus Escitalopram for Depression, New England Journal of Medicine (2021). This article is for education only and is not medical advice.